X0306 4 2016-11-29 1 0001338042 Aegerion Pharmaceuticals, Inc. AEGR 0001247015 BARER SOL J C/O AEGERION PHARMACEUTICALS, INC. ONE MAIN STREET, SUITE 800 CAMBRIDGE MA 02142 1 0 0 0 Common Stock 2016-11-29 4 D 0 29890 D 0 D Stock Option (Right to Buy) 19.25 2016-11-29 4 D 0 19927 D 2014-05-01 2021-05-05 Common Stock 19927 0 D Stock Option (Right to Buy) 17.64 2016-11-29 4 D 0 9988 D 2014-06-01 2021-06-01 Common Stock 9988 0 D Stock Option (Right to Buy) 15.00 2016-11-29 4 D 0 12854 D 2015-06-05 2022-06-05 Common Stock 12854 0 D Stock Option (Right to Buy) 64.73 2016-11-29 4 D 0 14700 D 2014-06-26 2023-06-26 Common Stock 14700 0 D Stock Option (Right to Buy) 32.55 2016-11-29 4 D 0 5012 D 2015-06-26 2024-06-26 Common Stock 5012 0 D Stock Option (Right to Buy) 17.98 2016-11-29 4 D 0 18000 D 2016-06-26 2025-06-26 Common Stock 18000 0 D Disposed of in exchange for 30,665 common shares of Novelion Therapeutics Inc. pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. /s/ Jennifer Fitzpatrick, Attorney-in-fact 2016-11-30